Proteragen

Proteragen is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies targeting the complement system and other immune-mediated pathways. The company leverages a proprietary drug discovery platform to develop a robust pipeline of monoclonal antibodies and small molecules for rare diseases and ophthalmology. Its lead programs include inhibitors of Complement C5 and Factor B, aimed at treating conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Proteragen operates with a global footprint, maintaining research and development facilities in both China and the United States.